| Popis: |
Diabetes and related diseases are growing problem, which negatively affect populations around the world. According to experts, these indicators are expected to reach 7.7% or 439 million people by 2030. One of the main and serious complications of diabetes mellitus is diabetic foot ulcers. The analyzed studies have shown that wounds that penetrate the bones, recurrent wounds, wounds lasting more than 30 days, and wounds associated with peripheral vascular diseases are sources of risk of infection and subsequent amputation. The main clinical purpose of treating lower limb wounds is to heal quickly and completely, but even with the best care, these wounds often heal slowly, which requires specialists to find advanced treatments to reduce the risk of amputation. A significant part of the methods requires additional new therapeutic agents to remove the wound from the chronic inflammatory phase and heal it with normal epithelialization. This article discusses modern technologies for the treatment of diabetic foot ulcers using various products of the human amniotic membrane and bioengineered skin substitutes. Currently, there are more than 60 modern cellular and / or tissue drugs for the treatment of wounds, which makes it difficult to choose a suitable, safe and effective auxiliary therapy. According to various authors, the use of amniotic membrane products has demonstrated its high clinical effectiveness in comparison with standard therapy in the treatment of neurotrophic ulcers of the lower extremities in patients with diabetes mellitus. |
